Skip to main content

Table 2 Clinical characteristics, treatment and comorbidities of 14 nonsurvivors with COVID-19

From: Clinical characteristics of 14 COVID-19 deaths in Tianmen, China: a single-center retrospective study

Symptoms Nonsurvivors (n = 14)
Fever 11 (78.6%)
Cough 12 (85.7%)
Sputum production 4 (28.6%)
Dyspnea 10 (71.4%)
Myalgia 0
Chest tightness 2 (14.3%)
Headache 1 (7.1%)
Diarrhea 4 (28.6%)
Blood pressure
 Systolic, mm Hg 133.5 (16.0)
 Diastolic, mm Hg 78.1 (10.7)
Laboratory resultsa
 Leukocytes (3.5–9.5), ×  109/L, 9.9 (3.0)
 Lymphocyte count (1.1–3.2), × 109/L, 0.6 (0.3)
 Neutrophils (1.8–6.3), × 109/L 9.2 (2.9)
 C-reactive protein (≤6.0), × 109/L 156.8 (75.5)
Treatment
 High-flow nasal cannula 14 (100%)
 Mechanical ventilation
  Noninvasive 9 (64.3%)
  Invasive 3 (21.4%)
 Antiviral agents 14 (100%)
 Antibacterial agents 13 (92.9%)
 Antifungal agents 1 (7.1%)
 Glucocorticoids 10 (71.4%)
 Immunoglobulin 5 (35.7%)
 α-IFN 4 (28.6%)
 Renal replacement therapy 4 (28.6%)
Comorbidities
 Acute respiratory distress syndrome 13 (92.9%)
 Acute kidney injury 3 (21.4%)
 Liver dysfunction 3 (21.4%)
 Cardiac injury 4 (28.6%)
 Hyperglycemia 1 (7.1%)
 Multiple organ dysfunction syndrome 2 (14.3%)
 Bacteremia 2 (14.3%)
 Fungal septicemia 1 (7.1%)
  1. Data are shown as n (%) or mean (SD)
  2. aOne patient had incomplete data, n = 13
\